1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
OncoSec Medical Incorporated

OncoSec Medical Incorporated

ONCSQ
OncoSec Medical IncorporatedUS flagOther OTC
0.00
USD
- -
- -
596.00Market Cap
2010 Y
2011 Y
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-2.32
-261.28
-154.28
-295.25
-277.38
-367.73
-358.2
-233.73
-214.59
-94.43
-56.22
-30.2
-19.13
-14.3
Free Cash Flow per Basic Share
-0.76
-112.62
-278.82
-233.21
-219.21
-330.33
-257.97
-189.19
-127.69
-90.5
-44.1
-28.48
-18.13
-12.16
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-4.81
-266.24
-403.96
-550.82
-585.12
-806.35
-979.04
-1,034.56
-735.18
-512.65
-274.9
-168.34
-160.06
-146.42
Tangible Book Value per Share
-1.93
-353.12
167.5
147.72
868.34
565.98
373.71
116.55
125.7
75.73
18.46
25.16
3.21
-2.84
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
2
2
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
1
1
1
1
- -
- -
- -
- -
1
1
1
1
Net Income, GAAP
- -
-4
-2
-7
-12
-21
-27
-21
-39
-30
-42
-45
-34
-29
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
- -
-4
3
3
37
31
26
9
23
24
13
41
9
-1
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
6
5
4
2
Total Equity
- -
-2
4
5
38
33
28
11
23
24
14
38
6
-5
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Jul'22
Oct'23
Jan'23
ST Debt
2
2
1
LT Borrowings
- -
- -
2
LT Finance Leases
4
4
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2
2
3
Market Capitalization
3
2
- -

Working Capital

FRC

•

in mil. unless spec.
Jul'22
Oct'23
Jan'23
Total Current Assets
15
9
6
Cash, Cash Equivalents & STI
12
6
4
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
7
7
7
Payables & Accruals
5
5
6
ST Debt
2
2
1
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
78.81%
33.59%
-83.93%
Free Cash Flow
26.99%
15.5%
-23.97%
Net Income, GAAP
43.55%
16.39%
-24.33%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
-10.87
-8.21
-5.56
- -
-30.2
2022
-5.51
-5.54
-3.49
- -
-19.13
2023
-4.51
-2.65
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Company Description

APIChat
Full Time Employees
40
Sector
Healthcare
Industry
Biotechnology
Address
24 North Main Street Pennington NJ United States of America 08534
IPO Date
Apr 7, 2010
CIK
0001444307
Website
oncosec.com
Similar Companies
Trevi Therapeutics, Inc. (TRVI)
Poxel S.A. (POXEL.PA)
Paratek Pharmaceuticals, Inc. (PRTK)
Maze Therapeutics, Inc. (MAZE)
Mymetics Corp. (MYMXE)
Microbix Biosystems Inc. (MBX.TO)
Business
OncoSec Medical Incorporated (ONCSQ) develops late-stage immuno-oncology therapies that utilize a proprietary intratumoral DNA-based plasmid delivery platform, ImmunoPulse, featuring electroporation to enhance immune responses against solid tumors. Core products and services encompass TAVO (tavokinogene telseplasmid), an IL-12 DNA plasmid for intratumoral immunotherapy indicated for melanoma, triple-negative breast cancer, Merkel cell carcinoma, and squamous cell carcinoma of the head and neck; Visceral Lesion Applicator (VLA) for deeper tumor targeting; investigational combinations including TAVO with pembrolizumab (KEYNOTE-695 and KEYNOTE-890 trials), nivolumab, epacadostat, SARS-CoV-2 spike glycoprotein, and CXCL9; and pipeline candidates OMS-100 and OMS-102 for metastatic melanoma. The company targets patients with advanced cancers unresponsive to checkpoint inhibitors, operating primarily in the United States through clinical-stage development and global partnerships for commercialization in Asia. Founded in 2008 and headquartered in San Diego, California, OncoSec focuses on oncology segments including melanoma, breast cancer, and head and neck cancers, with clinical trials advancing in neoadjuvant settings for personalized tumor eradication. In recent developments, OncoSec closed a $1.33 million registered direct offering priced at-the-market under Nasdaq rules to support operations; received positive FDA feedback on a proposed neoadjuvant melanoma program; continues recruitment in the KEYNOTE-890 Phase 2 trial for triple-negative breast cancer with TAVO and pembrolizumab; and maintains strategic licensing agreements granting exclusive rights to Grand Decade Developments (China Grand Pharmaceutical affiliate) and Sirtex for TAVO and VLA in Greater China and 35 Asian countries. The firm relocated its headquarters to enhanced facilities in San Diego's Sorrento Mesa biotech hub, consolidating research, clinical, and administrative functions to bolster development efficiency.